

Adjuvant radiotherapy post microvascular reconstructive surgery (MRS) for patients with locally advanced head and neck cancer – when and how?

Bogusław Maciejewski¹, Małgorzata Stąpór-Fudzińska², Daniel Bula³, Adam Maciejewski³, Łukasz Krakowczyk³, Agnieszka Niewczas⁴

¹Div. Research Programmes, Maria Skłodowska-Curie National Research Institute of Oncology, Gliwice Branch, Gliwice, Poland

²Dept. Radiotherapy Planning, Maria Skłodowska-Curie National Research Institute of Oncology, Gliwice Branch, Gliwice, Poland

³Oncologic and Reconstructive Surgery Ward, Maria Skłodowska-Curie National Research Institute of Oncology, Gliwice Branch, Gliwice, Poland

⁴Plastic Surgery Ward, Lower-Silesian Specialistic Hospital, Wrocław, Poland

For many decades palliation (radiotherapy, chemotherapy or symptomatic treatment) was the only therapeutic solution for locally very advanced head and neck cancer. In the mid 70s, H. Buncke carried out pioneering microvascular reconstructive surgery (MRS) as a radical treatment. Since that time, the MRS has been accepted around the world as a successful radical therapy, not only for head and neck (H&N) cancers. A part of the H&N cancers need however post-MRS radiotherapy (RT). Based on the 20 year experience of the Institute of Oncology in Gliwice with MRS (about 2500 patients), D. Bula has defined local recurrence risk factors. Dutch studies convincingly documented the prognostic value of the estimated molecular profiles of the resected margins as additional risk factors. The use of conventional 2.0 Gy/fraction post-MRS-RT result in a high risk of the inserted reconstructive flap necrosis or rejection. Therefore, a novel IMRT-VMAT technique with 50 Gy given in 1.5–1.6 Gy/fraction has been designed which allows to almost eliminate the flap from the irradiated volume and therefore minimizes recurrence and/or flap rejection to almost zero. The present paper shows objectively selected a cluster of patients being the candidate to post-MRS safe and effective VMAT radiotherapy.

Key words: advanced head and neck cancer, microvascular reconstructive surgery, criteria for post-op. VMAT radiotherapy

When and why did MRS begin?

Worldwide, nearly 600 000 patients are annually diagnosed with squamous cell head and neck cancer and about 60% of them have locally very advanced disease with or without infiltration (destruction) of local bone structures [T4N0(+)]. Locoregional recurrence are the predominant most failure resulted from uncontrolled microdisease. For decades, palliative radiotherapy or

symptomatic pain release therapy have been used as the only solution. As the result overall survival (OS) was only estimated but not the cure rate, because it has never been achieved [1, 2]. Generally, 5-year OS was low, on average about 10–15% (fig. 1, bottom survival curves) which raised to about 30–35% after radiotherapy combined with concurrent chemotherapy (usually single agent – cisplatin). The rate of patients with symptomatic therapy,

How to cite:

Maciejewski B, Stąpór-Fudzińska M, Bula D, Maciejewski A, Krakowczyk Ł, Niewczas A. *Adjuvant radiotherapy post microvascular reconstructive surgery (MRS) for patients with locally advanced head and neck cancer – when and how?* NOWOTWORY J Oncol 2022; 72: 303–307.

This article is available in open access under Creative Common Attribution-Non-Commercial-No Derivatives 4.0 International (CC BY-NC-ND 4.0) license, allowing to download articles and share them with others as long as they credit the authors and the publisher, but without permission to change them in any way or use them commercially.




Figure 1. Survival after palliative radiotherapy (RT) or chemoradiation (RT + CHT) compared with disease-free survival (DFS) after microvascular reconstructive surgery (MRS) with or without adjuvant RT

mainly painkillers, has still remained pretty high and patients quality of life was usually very poor. Patients with advanced tumors, often accompanied with pathologic bone (mandible or maxilla) infiltration and local necrotic lesions had no chance to be cured.

Incidentally, large tumor regression after palliative chemoradiation led to radicalization of therapeutic procedures (surgery), which sometimes (rarely) resulted in local tumor control, however with a high risk of local recurrence. Therefore, the overall rate of local tumor control with disease-free survival was very low (a few percent) and lasted not longer than 2–3 years. For the majority of very advanced head and neck (H&N) cancer patients prognosis was not optimistic and although palliative therapy resulted in prolonged survival, their quality of life became worse and worse and was accompanied with increasing pain and deteriorating speech, in addition to problems swallowing and eating. Such poor perspectives for palliative therapeutic options lasted for many decades till the 70s.

In 1973, a significant breakthrough was initiated by Harry Buncke's pioneering work in which he transferred an island flap to reconstruct defect in the upper part of the feet. In the same year, Daniel and Taylor [3] repeated this reconstructive microvascular surgery. They, with many other pioneers [4–10] developed core principles of reconstructive microsurgery which are still pertinent today. This therapeutic procedure has quickly spread across US, European and Far South-East medical and oncology centers.

Microvascular reconstructive surgery (MRS) of locally advanced, not only head and neck cancers, should be considered as a milestone step because it has offered a radical outcome and long-term local tumor control, instead of the previous palliation and short-term survival. In the Institute of Oncology in Gliwice in 2000, the MRS has enriched methods

and techniques of oncological surgery, and during the last 20 years about 2500 patients with advanced head and neck and other localization were successfully treated using the MRS. The overall 5-year disease-free survival rate increased to 88–90% (fig. 1, top curve) which clearly testifies to the tremendous improvements compared with previous results of palliative therapy. At the beginning of the MRS, the use of simple flaps gradually progressed into perforator, prefabricated, prelaminated, and chimeric flaps. Theoretically any tissue of any size from the body can be harvested using 135 different flaps, among which there are 65 types of free flaps. It allows the choice of a proper one for individual patient. Hidalgo et al. [11] pointed out that only seven free-flap donor sites are sufficient to solve 98% of microsurgical problems in oncology.

Although MRS has been a highly effective local therapy, there is still about 10–15% risk of local tumor recurrence and a few percent of postoperative local complications (flap necrosis). Thus, there is undoubtedly room for postoperative radiotherapy (RT), but it is still an open question whether all or only carefully selected patients need this RT as adjuvant therapy.

When should post-MRS radiotherapy should be applied?

Bula [12] analyzed the results of MRS in 119 patients with locally very advanced midface cancer, among which 85% were in stage T4N0(+) and in 63% of them four or more anatomical structures were involved. In 18 patients (10%), radicalism of surgical margins was defined as uncertain (very narrow margins?). One may ask what such uncertainty means. It is rather subjective than objective criterion for choosing post-op. RT. Using taxonomic statistics, the author established patient clusters with high and low risk of local recurrence. The cluster of patients with uncertain surgical margins, overweighed, with resection defect IIIA according Cordeiro scale [7, 8] and resected tumor size larger than 18 cm² strongly correlated with a high (about 90%) risk of local recurrence. On the contrary, cluster with radical margins (negative), normal weight, resection defect type IIA and a tumor size of about 4–8 cm² significantly ($p < 0.001$) correlated with almost no risk of local recurrence.

Therefore, patients from the first cluster likely seem to be candidates for postoperative RT. However, an important question arises as to whether the risk factor and parameters established by Bula can be considered as sufficient and adequate predictors for the post-MRS radiotherapy.

Studies of Nees et al. [13], Van Houten [14, 15] and Graveland [16], all from Vrije University Medical Center in Amsterdam (The Netherlands), have focused their studies on the molecular characteristics of minimal residual disease in surgical margins of head and neck cancer patients. Graveland [16] used two 5 μm sections from all surgical margins, which were histologically examined as to whether they were molecularly positive or negative. The specimens were used for immunohistochemical staining of the overexpression of the *p53* gene and *Ki-67* gene.




Figure 2. Example of immunohistochemical staining with: (A) a p53 positive field and (B) positive Ki-67 immunostaining [reprinted from Graveland et al. [16] with permission]





Figure 3. Local recurrence-free survival in relation to the molecular margin status (reprinted from Van Houten et al. Clin Cancer Res 2006; 6: 3803–3816, with permission)

A representative example of *p53* and *Ki-67*-positive fields is shown in the figure 2.

The *p53* and *Ki-67*-positive but histologically negative margins are the results of the cascade amplification of the EGFR, cyclin D1, cathepsin D, Cox-2, 9 p51, 3p, 17p 13, 11q 11 genes with LOH (loss of heterozygosity) which lead to gradual alteration of normal epithelial cells through hyperplasia and dysplasia to cancer cells (fig. 3, bottom part), clinically occurring as local recurrence of the primary tumor, although it has incorrectly been diagnosed the second primary tumor (SPT). Such local




Figure 4. Simple a single- or two field post-MRS stationary irradiation using 30 fractions of 2.0 Gy

recurrences (LR) develop from preneoplastic fields consisting of genetically altered normal mucosa cells that were not completely excised and they occur very early, during the first 10 months of the follow-up [13]. The results of the studies of Van Houten et al. [14, 15] have convincingly shown that cases with histologically negative but molecularly (*p53*, *Ki-67*, HPV) positive margins result in a significant ($p < 0.017$) decrease of the 5-year disease-free survival by about 30%, compared with cases with both molecular and histological negative margins (fig. 3).

Results of the Dutch studies clearly encourage to supplement surgical margins with molecular staining as a significant predictor of high risk of local recurrence after the MRS, which is more precise of the LR than the “uncertain margins” defined by Bula [12]. Together with the high risk cluster factors defined by this author, they could increase the precision of individual selection of high LR risk patients to post-MRS radiotherapy.

Methods and technique of post-MRS radiotherapy

Traditionally, the beam(s) of a single-or-two-field stationary irradiation of post-reconstructive area cover(s) both the inserted flap (block of healthy tissues) and the block of normal tissues surrounding the flap (fig. 4). It sounds illogical to include the flap into the irradiated area because it is a locus of minor resistance (*locus minoris resistantiae*) of normal tissue island. Although the risk of the LR may decrease, on the other hand, the increased risk of the post irradiation flap necrosis and/or rejection significantly increases, after conventional 2.0 Gy fractionated radiotherapy.




Figure 5. Example of VMAT radiotherapy technique with a single arc dose planning




Figure 6. Example of vertical VMAT dose distribution of 50 ± 5 Gy in 30–31 fractions within the ring of normal tissues surrounding the inserted flap and sharp dose fraction gradient to above ≤ 0.35 Gy per fraction deposited in the periphery of the flap tissue

Modern linear accelerators offer the use of a variety of intensity modulated RT (IMRT) techniques with non-uniform dose distribution using multileaf collimators (MLC). One such sophisticated technique is volumetric-modulated arc therapy (VMAT), which produces satisfactory dose distribution (fig. 5) to optimize the field shapes and beam intensities using a number of gantry angles. A significant advantage of the VMAT delivery is a reduction of the overall treatment time compared with conventional IMRT. For post-MRS adjuvant radiotherapy, the VMAT technique seems to be an optimal solution. This technique allows to plan the highest dose deposited in a ring of normal tissues surrounding the inserted flap likely containing microlesions of normal cells with potential genetic progression into cancer cells, and a sharp dose

gradient dose to almost zero within the inserted flap (fig. 6). An important point of such dose planning is that the dose per fraction should be not higher than 1.5–1.6 Gy which results in of dose per fraction reduced to 0.35 Gy within margins of the inserted flap. It allows to minimize or even eliminate the risk of the flap necrosis or rejection.

Summarizing, the recurrence risks factors defined by Bula [12] supplemented by an estimation of the molecular status of the respective margins increase the objective selection of patients as proper candidates to post-MRS adjuvant radiotherapy. The choice of the VMAT technique with the GTV_5 (ring of normal tissues surrounding the inserted reconstructive flap) total dose of about 50 Gy in 1.5–1.6 Gy dose per fraction seems to be the optimal solution for post-MRS radiotherapy as it likely lowers (even to zero) the risk of the inserted flap necrosis or rejection, and provides long term disease-free survival of patients with locally advanced head and neck cancer.

Conflict of interest: none declared

Bogusław Maciejewski

*Maria Skłodowska-Curie National Research Institute of Oncology
Gliwice Branch*

Div. Research Programmes

Wybrzeże Armii Krajowej 15

44-102 Gliwice, Poland

e-mail: boguslaw.maciejewski@io.gliwice.pl

Received: 22 Mar 2022

Accepted: 13 Apr 2022

References

1. Brizel DM, Gager JL. Locally advanced squamous carcinoma of the head and neck. in Principles and Practice of Radiation Oncology. ed. VII. Wolters Kluwer 2018: 885–894.
2. Merlano M, Vitale V, Rosso R, et al. Treatment of advanced squamous-cell carcinoma of the head and neck with alternating chemotherapy and radiotherapy. *N Engl J Med.* 1992; 327(16): 1115–1121, doi: 10.1056/NEJM199210153271602, indexed in Pubmed: 1302472.
3. Taylor GI, Daniel RK. The free flap: composite tissue transfer by vascular anastomosis. *Aust N Z J Surg.* 1973; 43(1): 1–3, doi: 10.1111/j.1445-2197.1973.tb05659.x, indexed in Pubmed: 4200573.
4. Tamai S. History of Microsurgery. *Plast Reconstr Surg.* 2009; 124: e282–e294, doi: 10.1097/prs.0b013e3181bf825e.
5. Koshima I, Yamamoto H, Hosoda M, et al. Free combined composite flaps using the lateral circumflex femoral system for repair of massive defects of the head and neck regions: an introduction to the chimeric flap principle. *Plast Reconstr Surg.* 1993; 92(3): 411–420, doi: 10.1097/00006534-199309000-00004, indexed in Pubmed: 8341739.
6. Parrett BM, Pomahac B, Orgill DP, et al. Prefabricated and prelaminated flaps for head and neck reconstruction. *Clin Plast Surg.* 2001; 28(2): 261–72, vii, indexed in Pubmed: 11400820.
7. Cordeiro PG, Santamaria E. A classification system and algorithm for reconstruction of maxillectomy and midfacial defects. *Plast Reconstr Surg.* 2000; 105(7): 2331–46; discussion 2347, doi: 10.1097/00006534-200006000-00004, indexed in Pubmed: 10845285.
8. Cordeiro PG, Chen CM. A 15-year review of midface reconstruction after total and subtotal maxillectomy: part I. Algorithm and outcomes. *Plast Reconstr Surg.* 2012; 129(1): 124–136, doi: 10.1097/PRS.0b013e318221dca4, indexed in Pubmed: 21681126.
9. Brown E, Suh HP, Han H, et al. Best New Flaps and Tips for Success in Microsurgery. *Plast Reconstr Surg.* 2020; 146(6): 796e–807e, doi: 10.1097/PRS.0000000000007331, indexed in Pubmed: 33234979.
10. Santamaria E, Cordeiro P. Reconstruction of maxillectomy and midfacial defects with free tissue transfer. *J Surg Oncol.* 2006; 94(6): 522–531, doi: 10.1002/jso.20490.

11. Hidalgo DA, Disa JJ, Cordeiro PG, et al. A review of 716 consecutive free flaps for oncologic surgical defects: refinement in donor-site selection and technique. *Plast Reconstr Surg.* 1998; 102(3): 722–32; discussion 733, indexed in Pubmed: 9727437.
12. Bula D. Ocena przydatności mikronaczyniowej chirurgii rekonstrukcyjnej w leczeniu miejscowo zaawansowanych nowotworów złośliwych środkowego piętra twarzy. Rozprawa doktorska. NIO-PIB, Oddział w Gliwicach, Gliwice 2021.
13. Nees M, Homann N, Discher H, et al. Expression of mutated p53 occurs in tumor-distant epithelia of head and neck cancer patients: a possible molecular basis for the development of multiple tumors. *Cancer Res.* 1993; 53(18): 4189–4196, indexed in Pubmed: 8364914.
14. van Houten VM, Tabor MP, van den Brekel MW, et al. Molecular assays for the diagnosis of minimal residual head-and-neck cancer: methods, reliability, pitfalls, and solutions. *Clin Cancer Res.* 2000; 6(10): 3803–3816, indexed in Pubmed: 11051222.
15. Van Houten VM. Mutated p53 as molecular marker for diagnosis of head and neck cancer. In: Van Houten VM. ed. *Molecular diagnosis and prognostic value of head and neck cancer in surgical margins.* Ponser and Looijnen, Wageningen, Amsterdam 2002: 79–100.
16. Graveland AP. Molecular diagnosis of minimal residual head and neck cancer and field cancellation. *Legatron Electronic Publ, Rotterdam* 2005: 21–54.
17. Wang TJC, Wun CHS, Cha KSC. Intensity-Modulated radiation treatment – Techniques and Clinical application. in *Principles and Practice of Radiation Oncology.* ed. VII. Wolters Kluwer 2018: 260–287.